Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
Surrey
WeybridgeKT13 0NY
GBRT: +44 1932959500
E: investor-relations@haleon.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
24,622
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,557.40 | 290.20 | -3.70% |
| CAC 40 | 7,274.95 | 324.03 | -4.26% |
| DAX 40 | 20,641.72 | 1,075.67 | -4.95% |
| Dow JONES (US) | 38,314.86 | 2,231.07 | -5.50% |
| FTSE 100 | 8,054.98 | 419.76 | -4.95% |
| HKSE | 20,849.29 | 2,000.52 | -8.76% |
| NASDAQ | 15,587.79 | 962.82 | -5.82% |
| Nikkei 225 | 31,942.88 | 1,837.70 | -5.44% |
| NZX 50 Index | 11,826.87 | 398.41 | -3.26% |
| S&P 500 | 5,074.08 | 322.44 | -5.97% |
| S&P/ASX 200 | 7,383.80 | 284.00 | -3.70% |
| SSE Composite Index | 3,151.63 | 190.38 | -5.70% |